The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
DUO: A phase 3 trial of the PI3K-δ,γ inhibitor IPI-145 versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Ian Flinn
Research Funding - Infinity Pharmaceuticals
Ulrich Jäger
No relevant relationships to disclose
Fritz Offner
No relevant relationships to disclose
Florence Cymbalista
No relevant relationships to disclose
Michael Hallek
No relevant relationships to disclose
Federico Caligaris-Cappio
Consultant or Advisory Role - Celgene; Janssen; Pharmacyclics
Honoraria - Celgene; Janssen; Pharmacyclics
Julio Delgado
No relevant relationships to disclose
Peter Hillmen
No relevant relationships to disclose
Matthew Steven Davids
Consultant or Advisory Role - Infinity Pharmaceuticals
David Donald Wright
No relevant relationships to disclose
James H. Essell
No relevant relationships to disclose
Bartrum W Baker
No relevant relationships to disclose
Walter Cosolo
No relevant relationships to disclose
Patrick Francis Kelly
Employment or Leadership Position - Infinity Pharmaceuticals
Patricia Harris
Employment or Leadership Position - Infinity Pharmaceuticals
Lixin Han
Employment or Leadership Position - Infinity Pharmaceuticals
Stock Ownership - Infinity Pharmaceuticals
Fiona Patterson
Employment or Leadership Position - Infinity Pharmaceuticals
Stephan Stilgenbauer
No relevant relationships to disclose